Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Open access
Bang, Y.J., Giaccone, G., Im, S.A., Oh, D.Y., Bauer, T.M., Nordstrom, J.L., Li, H., Chichili, G.R., Moore, P.A., Hong, S., Stewart, S.J., Baughman, J.E., Lechleider, R.J., Burris, H.A.·2017·Annals of Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 17

  1. Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 · DOI · Paper page
  2. Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 37, 687, 10.1016/S0140-6736(10)61121-X · DOI · Paper page
  3. Bianchini, 2014, The immune system and response to HER2-targeted treatment in breast cancer, Lancet Oncol, 15, e58, 10.1016/S1470-2045(13)70477-7 · DOI · Paper page
  4. Lehrnbecher, 1999, Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fc gamma receptor polymorphisms in control and disease populations, Blood, 94, 4220, 10.1182/blood.V94.12.4220.424k08_4220_4232 · doi:10.1182/blood.v94.12.4220.424k08_4220_4232
  5. Gianni, 2008, The “other” signaling of trastuzumab: antibodies are immunocompetent drugs, J Clin Oncol, 26, 1778, 10.1200/JCO.2007.15.7404 · DOI
  6. Nordstrom, 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties, Breast Cancer Res, 13, R123, 10.1186/bcr3069 · DOI · Paper page
  7. Tanner, 2004, Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer, Mol Cancer Ther, 3, 1585, 10.1158/1535-7163.1585.3.12 · DOI · Paper page
  8. Bruno, 2005, Population pharmacokinetics of trastuzumab in patient with HER2+ metastatic breast cancer, Cancer Chemother Pharmacol, 56, 361, 10.1007/s00280-005-1026-z · DOI · Paper page
  9. Agus, 2005, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer, J Clin Oncol, 23, 2534, 10.1200/JCO.2005.03.184 · DOI · Paper page
  10. Leyland-Jones, 2003, Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel, J Clin Oncol, 21, 3965, 10.1200/JCO.2003.12.109 · DOI · Paper page
  11. Tabrizi, 2006, Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov Today, 11, 81, 10.1016/S1359-6446(05)03638-X · DOI · Paper page
  12. Keizer, 2010, Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, 49, 493, 10.2165/11531280-000000000-00000 · DOI · Paper page
  13. Vugmeyster, 2012, Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World J Biol Chem, 3, 73, 10.4331/wjbc.v3.i4.73 · DOI · Paper page
  14. Baselga, 1996, Phase II study of weekly intravenous recombinant anti-p185HER monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J Clin Oncol, 14, 737, 10.1200/JCO.1996.14.3.737 · DOI · Paper page
  15. Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol, 16, 2659, 10.1200/JCO.1998.16.8.2659 · DOI · Paper page
  16. Carbonell Castellon, 2002, Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study, Proc Am Soc Clin Oncol, 21, 19a
  17. Ghahramani, 2003, Pharmacokinetics of Herceptin administered three-weekly compared to weekly: a simulation based on data from the clinical studies, Breast, 12, S40, 10.1016/S0960-9776(03)80128-5 · doi:10.1016/s0960-9776(03)80128-5

Cited by

See all 226

Metadata

Authors
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., Stewart, S. J., Baughman, J. E., Lechleider, R. J., & Burris, H. A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-04
Volume
28
Issue
4
Pages
855-861
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2582248920
Cited by
226
References
3
FWCI
9.48
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • MacroGenics, Inc.
  • Green Cross Corp

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. https://app.cochat.ai/papers/10.1093/annonc/mdx002
The paper
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., Stewart, S. J., Baughman, J. E., Lechleider, R. J., & Burris, H. A. (2017). First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of Oncology. https://doi.org/10.1093/annonc/mdx002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.